MEDELSIS is a medical device company that provides medical instruments for the highest standards of care, ensuring benefits to both physicians and patients. Self-described as dedicated to working with ophthalmologists.

MEDELSIS

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Alimera Sciences, Inc.

Azura Ophthalmics focuses on the development of ophthalmic keratolytics for the treatment of ocular conditions.

Azura Ophthalmics

Biocoat Incorporated specializes in supplying lubricious hydrophilic coatings, hydrophilic coating services, and custom polymers for medical devices.

Metric
Company Name	MEDELSIS	Alimera Sciences, Inc.	Azura Ophthalmics	Biocoat Incorporated
Symbol		ALIM
MSH ID	COM:MEDELSIS	COM:ALIMERASCIENCES	COM:AZURAOPHTHALMICS	COM:BIOCOAT
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical Devices	Drug Manufacturers - Specialty & Generic	Biopharmaceuticals	Medical Devices
Country	TR	US	US	US
Stage		Equity	Grant
Employee Count		154
Website	medelsis.com	alimerasciences.com	azuraophthalmics.com	biocoat.com
LinkedIn
Founders

Metric
Market Cap		291.28M
Enterprise Value
Monthly Web Traffic		42.70K
Web Traffic Growth		-0.95
Valuation
Raised Capital		20M

Metric
Revenue		80.75M
Revenue (LTM)
Revenue (NTM)
Gross Profit		61.17M
EBITDA		7.28M
Operating Income		-1.47M
Net Income		-20.13M
EPS		-0.79
Diluted EPS		-0.79
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.83
Operating Profit Margin		0.01
EBITDA Margin		0.09
Net Profit Margin		-0.15
Return on Equity		-0.34
Return on Assets		-0.10
Return on Capital Employed		0.01

COM:MEDELSIS

MEDELSIS

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-5.19
P/B Ratio		2.49
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		3.25
EV Multiple		122.86

Metric
Days Sales Outstanding		180.92
Days Payables Outstanding		242.59
Days Inventory Outstanding		55.34
Operating Cycle		205.56
Cash Conversion Cycle		27.60
Asset Turnover		0.66

Metric
Operating Cash Flow		-14.26M
Free Cash Flow		-89.79M
Cash Flow to Debt		-0.08
Operating Cash Flow/Sales		-0.06
Free Cash Flow Yield		-0.41

Metric
Cash & Equivalents		12.09M
Accounts Receivable		-17.16M
Inventory		1.88M
Goodwill
Debt to Capitalization		0.64
Debt to Assets		0.42
Current Ratio		2.73
Quick Ratio		2.62

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.02
R&D to Revenue		0.23
SG&A to Revenue		0.23